Related Experiment Video
Updated: Apr 14, 2026
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study
Introduction:
We aimed to understand the molecular pathways affected by bortezomib and arsenic trioxide treatment on myelomonocytoid cell line P39.
Methods:
Oligonucleotide microarray platforms were used for gene expression and pathway analysis. Confirmation studies were performed using quantitative real time PCR.
Results:
Bortezomib treatment has shown upregulated DIABLO and NF-κBIB (a NF-κB inhibitor) and downregulated NF-κB1, NF-κB2, and BIRC1 gene expressions. Combination treatment of the two compounds showed gene expression deregulations in concordance by the results of single bortezomib treatment. Especially, P53 was a pathway more significantly modified and a gene network centralized around the beta estradiol gene. Beta estradiol, BRCA2, and FOXA1 genes were remarkable deregulations in our findings.
Discussion And Conclusion:
Results support the suggestions about possible use of proteasome inhibitors in the treatment of high-risk myelodysplastic syndrome (MDS). NF-κB was observed as an important modulator in leukemic transformation of MDS.
Insights
Bortezomib and arsenic trioxide alter gene expression in myelomonocytoid cells, impacting pathways like NF-κB and P53. These findings suggest proteasome inhibitors may help treat myelodysplastic syndrome.
Area of Science:
- Molecular biology
- Cancer research
- Genomics
Background:
- Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell disorders.
- Understanding molecular pathways in MDS is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the molecular pathways affected by bortezomib and arsenic trioxide in the P39 myelomonocytoid cell line.
- To identify potential therapeutic targets for high-risk MDS.
Main Methods:
- Oligonucleotide microarray for gene expression and pathway analysis.
- Quantitative real-time PCR for confirmation studies.
Main Results:
- Bortezomib upregulated DIABLO and NF-κB inhibitor, downregulated NF-κB1, NF-κB2, and BIRC1.
- Combined treatment showed similar gene expression changes.
- P53 pathway and a beta estradiol-centered gene network were significantly modified.
- Beta estradiol, BRCA2, and FOXA1 gene expressions were notably deregulated.
Conclusions:
- Proteasome inhibitors show potential for treating high-risk MDS.
- NF-κB signaling plays a significant role in the leukemic transformation of MDS.
